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Background. Transplant recipients presenting with cytomegalovirus (CMV) disease at the time of diagnosis of CMV DNAemia 
pose a challenge to a preemptive CMV management strategy. However, the rate and risk factors of such failure remain uncertain.
Methods. Solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) recipients with a first episode 
of CMV polymerase chain reaction (PCR) DNAemia within the first year posttransplantation were evaluated (n = 335). Patient 
records were reviewed for presence of CMV disease at the time of CMV DNAemia diagnosis. The distribution and prevalence of 
CMV disease were estimated, and the odds ratio (OR) of CMV disease was modeled using logistic regression.
Results. The prevalence of CMV disease increased for both SOT and HSCT with increasing diagnostic CMV PCR load and with 
screening intervals >14 days. The only independent risk factor in multivariate analysis was increasing CMV DNAemia load of the 
diagnostic CMV PCR (OR = 6.16; 95% confidence interval, 2.09–18.11). Among recipients receiving weekly screening (n = 147), 
16 (10.8%) had CMV disease at the time of diagnosis of CMV DNAemia (median DNAemia load 628 IU/mL; interquartile range, 
432–1274); 93.8% of these cases were HSCT and lung transplant recipients.
Conclusions. Despite application of weekly screening intervals, HSCT and lung transplant recipients in particular presented 
with CMV disease at the time of diagnosis of CMV DNAemia. Additional research to improve the management of patients at risk of 
presenting with CMV disease at low levels of CMV DNAemia and despite weekly screening is warranted.
Keywords. CMV disease; CMV DNAemia; CMV PCR; cytomegalovirus; transplant recipient.
 
Cytomegalovirus (CMV) DNAemia, detected in plasma with 
CMV polymerase chain reaction (PCR), is known to frequently 
complicate the course after solid organ transplantation (SOT) 
and human stem cell transplantations (HSCT) [1, 2]. Without 
intervention, CMV DNAemia may progress to CMV end organ 
disease [3]. The essence of the preemptive approach for pre-
vention of CMV disease consists of CMV PCR measurements 
in whole blood or plasma at regular intervals after transplan-
tation, to detect and, if above a predefined threshold, treat 
CMV DNAemia before it causes clinical disease [4]. HSCT 
recipients are usually managed solely preemptively, whereas 
SOT recipients usually receive universal prophylaxis with val-
ganciclovir and/or preemptive follow-up after transplantation 
[2, 5]. Numerous previous studies have demonstrated that a 
high CMV DNAemia load in the blood compartment is among 
the most prominent risk factors for development of CMV dis-
ease [6–11]. To secure an early diagnosis while the DNAemia 
load remains low and the probability to prevent progression to 
CMV disease is high, current transplantation guidelines recom-
mend weekly screening when applying a preemptive strategy 
for CMV prevention [2, 5]. The effectiveness of the preemptive 
strategy mainly depends on the meticulousness of, and adher-
ence to, the screening program. However, some recipients may 
develop CMV end organ disease already at low or undetect-
able CMV PCR levels in the blood compartment; in particu-
lar, CMV pneumonia and CMV gastrointestinal (GI) disease 
have this tendency [12–16]. Recipients showing signs of CMV 
end organ disease at the diagnosis of CMV DNAemia implies 
failure of the preemptive strategy; however, the extent of this 
challenge in the setting of preemptive follow up remains to be 
fully elucidated. The aims of the present study were to assess 
the prevalence of CMV disease in a large, unselected cohort of 
transplant recipients at the time of diagnosis of the first episode 
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of posttransplant CMV DNAemia in plasma, with special focus 
on potential CMV disease presenting at low levels of CMV 
DNAemia. Furthermore, we aimed to identify the main inde-
pendent risk factor(s) of CMV disease at diagnosis of CMV 
DNAemia.
METHODS
Patients
Consecutive SOT (recipients of heart, lung, liver, kidney, and 
pancreas/kidney transplantation) and HSCT (recipients of 
myeloablative conditioning [MAC], nonmyeloablative condi-
tioning [NMA], and umbilical cord blood  [UCB]) recipients 
transplanted between January 1, 2010 to December 31, 2015 
at Rigshospitalet, Copenhagen, Denmark were considered for 
inclusion in the study (n = 1673). Recipients with a known CMV 
immunoglobulin (Ig)G of the donor (D) and recipient (R) of 
either D+/R+, D−/R+, or D+/R− at transplantation (n = 1268) 
and who experienced a first episode of posttransplant CMV 
DNAemia (n = 335) in the blood compartment within the first 
year of transplantation were included in the present study.
The standard immunosuppressive regimens used at our cen-
ter have been described previously [17]. The standard condi-
tioning regimen for MAC consists of 12 grays of total body 
irradiation and a high dose (120 mg/kg) of cyclophosphamide.
Management of CMV
The recipients were stratified according to subsequent risk of 
CMV DNAemia after transplantation as being either at high, 
intermediary, or low risk, based on the D/R CMV IgG serosta-
tus at transplantation [18, 19]. The high-risk group comprised 
D+/R− SOT and D−/R+ HSCT recipients. The D+/R+ com-
prised the intermediary risk group for both types of transplan-
tations, and the low-risk group comprised D−/R+ for SOT and 
D+/R− for HSCT.
CMV management in SOT and HSCT recipients at our cen-
ter has been described previously [20]. In short, SOTs receive 
3  months of prophylaxis and subsequent preemptive follow 
up. In case of side effects to valganciclovir prophylaxis, this is 
stopped and preemptive screening is commenced. Human stem 
cell transplantations are managed solely preemptively during 
the first year posttransplant.
CMV PCR monitoring was performed on plasma samples. 
COBAS AmpliPrep/COBAS TaqMan has been used since 2011, 
and before that the COBAS Amplicor kit was used [21]. In 2011, 
there was an overlap in the use of the 2 PCR platforms; during 
this time period, all tests were simultaneously tested on both 
platforms, determining a conversion factor between the COBAS 
Amplicor kit and the COBAS AmpliPrep/COBAS TaqMan at 
1:1. The COBAS AmpliPrep/COBAS TaqMan conversion factor 
(1 copy/mL = 0.91 IU/mL) has been used to convert all CMV 
viral loads into IU/mL. The lower limit of detection was 273 
IU/mL.
CMV Infection and Disease Definitions
The present study focused exclusively on the time of diagnosis 
of the first episode of posttransplant CMV DNAemia detected 
in plasma using CMV PCR, defined as the date of the first of 2 
consecutive plasma CMV PCR samples ≥273 IU/mL or of the 
first CMV PCR sample ≥2730 IU/mL.
The presence of CMV disease was assessed by a physician 
based on patient records at the time of diagnosis of CMV 
DNAemia, according to the present guidelines [3] (summarized 
in Supplementary Table 1). For CMV pneumonia and CMV GI 
disease, all potential copathogens detected ±7 days within the 
diagnostic CMV PCR were evaluated. For CMV GI disease in 
HSCT recipients, evidence of concurrent GI graft-versus-host 
disease (gvhd) was also evaluated in case of a concurrent biopsy.
The overall prevalence of CMV disease, as well as the prev-
alence after stratification for overall type of transplantation 
(SOT vs HSCT), was calculated. The prevalence of CMV dis-
ease was calculated for the respective types of transplantation 
in 4 different intervals depending on the DNAemia load in the 
diagnostic CMV PCR (DNAemia load [IU/mL]; <910, ≥910–
2730, >2730–18 200, >18 200). Finally, the cohort was stratified 
into 4 groups depending on the time between the last negative 
CMV PCR sample and the consecutive diagnostic CMV PCR 
(<8  days, 8–14  days, >14–30  days, or >30  days), allowing for 
comparison of the median diagnostic CMV DNAemia load and 
prevalence of CMV disease between asymptomatic cases and 
cases with CMV disease. Univariate and multivariate logistic 
regression was used to determine the odds ratio (OR) for CMV 
disease at diagnosis of CMV DNAemia.
Statistical Analyses
Standard descriptive statistics were used to compare baseline 
characteristics at the time of transplantation as well as differ-
ences in CMV DNAemia loads and proportions between the 
groups of recipients. Risk factors for CMV disease at the time 
of the diagnostic CMV PCR were explored using univariate and 
multivariate logistic regression adjusted for relevant confound-
ers and tested for relevant interactions. All analyses were per-
formed in SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC), 
and P values ≤.05 were considered statistically significant.
RESULTS
Recipient Characteristics
Three hundred thirty-five recipients (178 SOT; 157 HSCT) 
were diagnosed with first-time CMV DNAemia in plasma with 
CMV PCR. Baseline demographics at the time of transplanta-
tion such as age and gender were comparable between SOT and 
HSCT recipients (Table  1). The SOT recipients had a higher 
proportion of low-risk patients developing CMV DNAemia 
compared with the HSCTs (P  =  .002), but the distribution of 
high and intermediary risk profiles were comparable between 
the 2 groups of transplantation (Table 1).
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Of the 157 HSCT recipients, 137 were matched unrelated 
donors, and the remaining 20 were matched family (parent or 
sibling) donors.
CMV DNAemia.
 Due to the administration of valganciclovir prophylaxis to the 
SOT population, CMV DNAemia developed later in SOT recip-
ients compared with HSCT recipients (P  <  .0001) (Table  2). 
The median DNAemia load of the diagnostic CMV PCR was 
higher in SOT recipients compared with the HSCT recipients 
(diagnostic CMV PCR 719 IU/mL [interquartile range {IQR}, 
282–2548] vs 455 IU/mL [IQR, 273–910]; P = .0005). The over-
all median time of days from the last negative CMV PCR to 
the first positive CMV PCR (eg, the screening interval) was 
significantly longer in SOT recipients than HSCT recipients 
(P < .0001) (Table 1).
Overall CMV Disease at the Time of CMV DNAemia Diagnosis.
Overall, 49 of 335 (14.6%; 95% confidence interval [CI], 10.8–
18.4) of the included recipients had CMV disease at the time of 
diagnosis of the first episode of CMV DNAemia, corresponding 
to an overall 18.5% (95% CI, 12.8–24.2) of the SOT recipients 
and 10.2% (95% CI, 5.5–14.9) of the HSCT (Figure 1). The clin-
ical manifestations detected in the cohort at the time of diagnosis 
of CMV DNAemia were CMV syndrome, CMV pneumonia, 
and CMV GI disease, and the prevalence and type of CMV dis-
ease differed between SOT and HSCT recipients (Figure 1 and 
Supplementary Table 2). Overall, there were 64 deaths during 
the first year of transplantation; of these, 13 occurred in patients 
who presented with CMV disease at CMV DNAemia diagno-
sis. There were 20 deaths occurring within 28  days after the 
last positive CMV PCR of the first CMV DNAemia episode; of 
these, 6 occurred in patients who presented with CMV disease 
at CMV DNAemia diagnosis.
CMV Disease and CMV DNAemia Load.
Cases with CMV disease had a significantly higher median 
DNAemia load compared with the asymptomatic episodes of 
CMV DNAemia (3913 IU/mL [IQR, 728–91 000] vs 478 IU/
mL (IQR, 273–1001); P  <  .0001). Overall, the prevalence of 
CMV disease in SOT and HSCT stratified for the DNAemia 
load in the diagnostic CMV PCR increased with increasing 
load of DNAemia (Figure  2). However, for both main types 
of transplantations, CMV organ disease could be found at the 
time of diagnosis already at DNAemia levels <910 IU/mL, with 
a prevalence of 8.9% (95% CI, 3.4–14.4) for the SOT recipients 
and 5.1% (95% CI, 1.1–9.1) for the HSCT recipients (Figure 2). 
All of the SOT recipients with CMV disease at diagnostic CMV 
Table  1. Characteristics of Transplant Recipients With a First Episode of Cytomegalovirus DNAemia Detected in Plasma, Stratified for Type of 
Transplantation
Features of Included Recipients and the First Episode of CMV DNAemia
Solid Organ Recipients
N = 178
Bone Marrow Recipients
N = 157 P Value
Characteristics of Recipients
Median age at transplantation (IQR) 50 (38–59) 48 (33–61) .6
Gender (% males) 98 (55.06%) 100 (63.69%) .1
Type of Transplantation (% of Transplantation Type)
Kidney 74 (41.57%) N.A.
Liver 42 (23.59%) N.A.
Lung 52 (29.21%) N.A.
Heart 8 (4.49%) N.A.
Kidney/Pancreas 2 (1.12%) N.A.
MAC N.A. 76 (48.41%)
NMA N.A. 68 (43.31%)
UCB N.A. 13 (8.28%)
Risk of CMV Infection Associated With Donor and Recipient CMV IgG Serostatusa
Proportion of recipients at high risk 86 (48.31%)  87 (55.41%) .2
Proportion of recipients at intermediary risk 72 (40.45%) 66 (42.04) .8
Proportion of recipients at low risk 20 (11.24%) 4 (2.55%) .002
Characteristics of the First Episode of CMV DNAemia
Median time (days) from transplantation to CMV DNAemia (IQR) 120 (63–148) 48 (35–62) <.0001
Median time (days) from the last negative CMV PCR to the first positive CMV PCR of 
the CMV DNAemia (IQR)
18 (7–28) 7 (6–9) <.0001
Median DNAemia load (IU/mL) of the first positive CMV PCR sample of the CMV 
DNAemia episode (IQR)
719 (282–2548) 455 (273–910) .0005
Abbreviations: CMV, cytomegalovirus; IgG, immunoglobulin G; IQR, interquartile range; MAC, myeloablative conditioning; N.A., not applicable; NMA, nonmyeloablative conditioning; PCR, 
polymerase chain reaction; UCB, umbilical cord blood.
aRisk of CMV DNAemia according to donor (D)/recipient (R) CMV IgG serostatus (±) at the time of transplantation. For solid organ recipients, high risk of CMV DNAemia is associated with 
D+/R−, whereas D−/R+ represent the high-risk group among hematopoietic stem cell recipients. For both types of transplantation, D+/R+ is associated with an intermediary risk of CMV 
infection. The low-risk group constitutes D−/R+ for solid organ recipients and D+/R− for hematopoietic stem cell recipients.
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PCR levels <910 IU/mL were recipients of lung transplanta-
tion (1 probable GI disease; 8 cases of CMV pneumonia [3 
proven, 4 probable, and 1 possible]); for HSCT recipients, the 
GI diseases present in this interval of CMV DNAemia were 
proven in 4 cases and probable in 2 cases. The DNAemia load 
of the diagnostic CMV PCR increased with longer screening 
interval among the symptomatic recipients (Figure 3). In com-
parison, this trend was less pronounced among the asymp-
tomatic recipients. Furthermore, the symptomatic episodes 
of CMV DNAemia had significantly higher CMV DNAemia 
load regardless of screening interval. The proportion of CMV 
disease was 10.8% (95% CI, 5.8–15.8) and 9.0% (95% CI, 2.6–
15.3), already at screening intervals <8 days and ≥8–14 days, 
respectively, and increased to 27.0 (95% CI, 12.7–41.3) in 
patients with screening intervals >30 days. Among the recip-
ients constituting the 10.8% with CMV disease despite weekly 
screening, 15 of 16 (93.7%; 95% CI, 81.8–105.6) cases were 
organ disease (GI disease: 9 HSCT and 1 lung recipient; CMV 
pneumonia: 5 lung transplant recipients), with a median 
diagnostic DNAemia load at 628 IU/mL (IQR, 432–1274). 
More importantly, only 2 of these cases of organ disease were 
possible cases (1 lung transplant with pneumonia and 1 NMA 
recipient with GI disease). The one case with CMV syndrome 
was a CMV IgG D+/R− kidney recipient who was diagnosed 
with CMV DNAemia at 91 000 IU/mL 5 days after the last neg-
ative CMV PCR. In the multivariate logistic regression model, 
only CMV DNAemia load >2730 IU/mL remained an inde-
pendent risk factor for CMV disease at the time of diagnosis of 
CMV DNAemia, and the OR increased with increasing diag-
nostic DNAemia load (Table  2). There were no interactions 
between the type of transplantation (SOT vs HSCT) and the 
viral load in the diagnostic CMV PCR.
DISCUSSION
In this study, we found that despite application of the recom-
mended weekly screening interval for preemptive screening, 
10.8% of the patients had concomitant CMV disease at the time 
of CMV DNAemia diagnosis. This indicates that a subset of 
Table 2. Univariate and Multivariate Logistic Regression of Risk Factors for Cytomegalovirus Disease Among 335 Transplant Recipients With a First CMV 
DNAemia Detected in Plasma With CMV PCR
Factors
Univariate Multivariate
OR (95% CI) P Value OR (95% CI) P Value
Baseline Characteristics
 Male gender 1.00 (0.54–1.86) .99 0.85 (0.41–1.78) .67
Age at transplantation 1.04 (0.87–1.24) .66 1.02 (0.82–1.27) .85
Year of Transplantation
2010 1.93 (0.71–5.21) .20 1.18 (0.35–4.02) .79
2011 1.35 (0.46–3.92) .59 1.25 (0.36–4.31) .72
2012 1.10 (0.44–2.80) .83 0.93 (0.32–2.71) .89
2013 1.33 (0.50–3.53) .56 0.81 (0.24–2.74) .73
2014 0.65 (0.23–1.83) .42 0.77 (0.24–2.44) .66
2015 Ref. Ref.
Type of Transplantation
HSCT Ref. Ref.
SOT 2.01 (1.06–3.81) .03 1.18 (0.50–2.83) .71
Risk associated with CMV IgG serostatusa
High risk Ref. Ref.
Intermediary and low risk 0.77 (0.42–1.42) .41 1.21 (0.58–2.54) .61
CMV DNAemia Load of the First Positive CMV PCR Sample (IU/mL)
CMV DNAemia load <910 Ref. Ref.
CMV DNAemia load ≥910–2730 1.76 (0.69–4.54) .24 1.85 (0.69–4.98) .22
CMV DNAemia load >2730–18 200 5.73 (2.15–15.23) .0005 6.16 (2.09–18.11) .001
CMV DNAemia load >18 200 28.71 (11.10–74.30) <.0001 44.86 (11.86–169.65) <.0001
Screening Intervalb
<8 days Ref. Ref.
≥8–14 days 0.81 (0.32–2.05) .65 0.59 (0.21–1.67) .32
>14–30 days 2.30 (1.08–4.91) .03 0.72 (0.25–2.13) .56
>30 days 3.03 (1.24–7.40) .01 0.38 (0.09–1.60) .19
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation; IgG, immunoglobulin G; OR, odds ratio; PCR, polymerase chain reaction; Ref., 
reference; SOT, solid organ transplantation.
aRisk of CMV DNAemia according to donor (D)/recipient (R) CMV IgG serostatus (±) at the time of transplantation. For solid organ recipients, high risk of CMV DNAemia is associated with 
D+/R−, whereas D−/R+ represents the high-risk group among hematopoietic stem cell recipients. For both types of transplantation, D+/R+ is associated with an intermediary risk of CMV 
infection. The low-risk group constitutes D−/R+ for solid organ recipients and D+/R− for hematopoietic stem cell recipients.
bBased on the interval of days between the last negative CMV PCR and the diagnostic CMV PCR of the CMV DNAemia episode.
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transplant recipients is at risk of failing the preemptive strategy 
despite application of recommended screening intervals.
Several previous studies demonstrated that the CMV viral 
load can predict the clinical outcome of CMV infection in 
transplant recipients and that the risk of CMV disease increases 
with increasing CMV DNAemia load [7–11]. In line with this, 
the OR for CMV disease at the time of diagnosis of CMV 
DNAemia increased with increasing DNAemia load of the 
diagnostic CMV PCR in the present study (Table 2). However, 
the CMV DNAemia load was <910 IU/mL for the majority of 
the weekly screened recipients presenting with CMV disease 
concurrent with the CMV DNAemia diagnosis (Figure 3). The 
infectious phenotypes for CMV disease occurring at these low 
levels of CMV DNAemia were mainly confined to CMV GI dis-
ease in HSCT recipients and CMV pneumonia in lung trans-
plant recipients.
Other studies have reported similar observations of CMV 
disease being compartmentalized in organs such as the lung and 
GI canal, with corresponding low or absent CMV DNAemia in 
the blood compartment [13–16, 22–24]. The concept of low or 
absent CMV DNAemia concurrent with CMV end organ dis-
ease poses a massive challenge to CMV screening strategies, 
because the success of screening and subsequent preemptive 
treatment relies on the hypothesis that CMV disease is precip-
itated by CMV DNAemia and that the risk is increasing with 
higher DNAemia loads [6]. Although there are studies focus-
ing on the progression of CMV DNAemia to CMV disease on 
preemptive treatment [25], very few observations have focused 
on patients managed with preemptive screening yet failing 
already at the time of diagnosis of CMV DNAemia. Our results 
indicate that low diagnostic CMV DNAemia levels do not rule 
out CMV GI disease in HSCT recipients or CMV pneumonia 
in lung transplant recipients, and it adds further evidence to the 
current clinical practice that patients with symptoms of these 
phenotypes of organ invasive disease should be investigated 
regardless of plasma DNAemia load and, in particular, if pres-
ent in any of these types of transplantation recipients.
Although the preemptive strategy has proven successful 
in many previous studies to prevent CMV disease [4, 26, 27], 
this observation also underlines the importance of finding 
alternatives to the solely preemptive strategy applied to HSCT 
recipients. There are several ongoing trials with newer drug 
compounds (such as letermovir for prophylaxis) that poten-
tially could be administered to HSCT recipients [28–31], 
delaying CMV DNAemia to a potentially more stable period 
posttransplantation. On a similar note, 3  months of prophy-
laxis and subsequent screening for detection and diagnosis of 
CMV pneumonia might not be sufficient for the lung transplant 
recipients, reflecting the ongoing debate of duration of prophy-
laxis in this group of recipients [32, 33]. In fact, since this study, 
SOT HSCT
Type of clinical manifestation
SOT (n=178)
% %[95% CI] [95% CI]
81.5 89.875.8–87.2 85.1–94.5
18.5 10.212.8–24.2 5.5–14.9
0.06 1.3–0.3–0.4 –0.5–3.1
1.7 3.2–0.2–3.6 0.4–6.0
0 3.80 0.8–6.8
2.8 00.4–5.2 0
3.9 01.1–6.7 0
3.4 1.90.7–6.1 –0.2–4.0
6.2 NA2.7–9.7 NA
NA
HSCT (n=157) Colour
coding
Asymptomatic CMV DNAemia
Overall CMV disease
Possible CMV GI disease
Probable CMV GI disease
Proven CMV GI disease
Possible CMV pneumonia
Probable CMV pneumonia
Proven CMV pneumonia
CMV syndrome
Figure 1. Prevalence and type of cytomegalovirus (CMV) disease at the first CMV DNAemia episode in solid organ transplantation (SOT) and hematopoietic stem cell 
transplantation (HSCT) recipients. No other types of CMV disease were observed. CI, confidence interval; GI, gastrointestinal; NA, not applicable.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/5/5/ofy080/4973012 by R
oyal Library C
openhagen U
niversity user on 06 February 2019
6 • OFID • Lodding et al
the valganciclovir prophylaxis has been prolonged for the lung 
transplant recipients in our cohort.
CMV GI disease and pneumonia are both complex diagnoses 
to establish. CMV infection has been associated with increased 
association with secondary bacterial and fungal infections and 
gvhd [15, 16, 22, 34]. For example, the clinical presentations 
of CMV GI disease and GI gvhd are very similar, and they are 
usually impossible to differentiate without an endoscopic inves-
tigation and biopsy [22, 35]. Thus, the presence of competing 
causes makes it difficult to discern the role of CMV as the cul-
prit or opportunistic bystander. For this study, we have applied 
the new definitions on CMV disease in transplant recipients [3], 
and we have reported concurrent competing causes. Our data 
imply the necessity to continue to investigate all biopsies from 
the GI canal for CMV in HSCT recipients with GI symptoms, 
regardless of their concurrent CMV DNAemia levels. Likewise, 
CMV pneumonia should be suspected in lung transplant recip-
ients with respiratory symptoms irrespective of plasma PCR 
results, and, if possible, bronchoalveolar lavage (BAL) CMV 
PCR should be performed [15].
There are some limitations in this study. The plasma CMV 
PCR was collected as a part of the routine prospective follow 
up, but the evaluation of the potential presence of CMV disease 
in the CMV DNAemia episodes were performed retrospectively 
100%
80
SOT, n=102
VL < 910 IU/mL
Intervals of DNAemia load at time of CMV
DNAemia diagnosis
VL <910 IU/mL
Asymptomatic CMV DNAemia
Asymptomatic CMV DNAemia
Asymptomatic CMV DNAemia
Asymptomatic CMV DNAemia
Overall CMV disease
Overall CMV disease
Overall CMV disease
Overall CMV disease
VL ≥910–2730 IU/mL
VL >2730–18 200 IU/mL
VL >18 200 IU/mL
VL ≥ 910–2730 IU/mL VL > 2730–18 200 IU/mL VL > 18 200 IU/mL
HSCT, n=117 HSCT, n=27 HSCT, n=10 HSCT, n=3**
% with asymptomatic
CMV DNAemia
% with CMV syndrome
(SOT recipients only)*
% with CMV pneumonia
% with CMV GI disease
SOT, n=34 SOT, n=17 SOT, n=25
60
40
20
0
SOT
% %[95% CI] [95% CI]
91.1 94.985.6–96.6 90.9–98.9
8.9 5.13.4–14.4 1.1–9.1
94.1 81.586.2–102.0 66.9–96.1
5.9 18.5–2.0–13.8 3.9–33.1
70.6 70.048.9–92.3 41.6–98.4
29.4 30.07.7–51.1 1.6–58.4
32.0 33.3**13.7–50.3 –20.0–86.6
68.0 66.7**49.7–86.3 13.4–120.0
HSCT
Figure 2. Prevalence of cytomegalovirus (CMV) disease (by type) according to diagnostic DNAemia load at the first episode of CMV DNAemia in solid organ transplant 
(SOT) and hematopoietic stem cell transplant (HSCT) recipients. *Only applicable to SOT recipients. **Please note the low number of HSCT recipients in this interval of CMV 
DNAemia. CI, confidence interval; VL, viral load.
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from patient journal records. The CMV PCR results presented 
in the current study are transformed using the international 
standard introduced by the World Health Organization [36]; 
however, it is important to recall that some variability still 
remains despite this when interpreting the reported viral loads 
[37, 38]. Furthermore, the current observations were based on 
CMV PCR performed in plasma, and, as such, the results may 
not be directly transferable to other cohorts that, for example, 
use whole blood for CMV PCR screening [39]. Finally, the aim 
of this study was to evaluate the presence of CMV disease at 
the time of the diagnostic CMV PCR in plasma of the first epi-
sode of posttransplant CMV DNAemia. As such, we have not 
evaluated the negative CMV PCRs of our cohort for presence 
of CMV disease, and, as a consequence, there may be isolated 
cases of organ disease with concurrent negative plasma CMV 
PCR. In fact, we have recently investigated the diagnostic 
yield of BAL CMV PCR in lung transplant recipients, where 
we demonstrated the presence of proven and probable CMV 
pneumonia with concurrent negative plasma CMV PCRs [15]. 
However, a systematic review of all pathology data during CMV 
PCR-negative time periods remains to be performed before we 
can ascertain the number of biopsy proven cases of CMV organ 
disease, regardless of CMV PCR results.
CONCLUSIONS
In conclusion, increasing viral load at the time of diagnosis of 
CMV DNAemia was the most prominent risk factor for CMV 
disease. However, a remarkably large proportion of the episodes 
with CMV disease occurred in recipients who were weekly 
screened and who were diagnosed at levels of CMV DNAemia 
<910 IU/mL. These cases consisted almost exclusively of HSCT 
and lung transplant recipients, who presented with CMV GI 
disease and CMV pneumonia. These observations underline 
the need for additional research to improve the understanding 
of the factors explaining the development of CMV disease at low 
CMV PCR viral loads, especially for CMV GI disease in HSCT 
recipients and CMV pneumonia in lung transplant recipients.
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